Evotec SE (0IRF.L)

25,98 +0,07 (+0,25%) Alla chiusura: 08:32AM BST

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 5.022

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Laetitia Rouxel	CFO & Member of Management Board	890k	N/D	1975
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	748k	N/D	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	582k	N/D	1970
Dr. Matthias Evers Ph.D.	Chief Business Officer & Member of Management Board	594k	N/D	1973
Dr. Christian Wojczewski	Chief Executive Officer	N/D	N/D	1972
Ms. Aurelie Dalbiez	Chief People Officer & Member of Management Board	N/D	N/D	1977
Ms. Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	N/D	N/D	N/D
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG	N/D	N/D	N/D
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/D	N/D	1971
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Governance aziendale

L'ISS Governance QualityScore di Evotec SE al 1 settembre 2024 è 1. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.